This finding has not been confirmed in the CREDENCE trial comparing canagliflozin with placebo in patients with T2DM and chronic kidney disease, nor cardiovascular outcomes with other SGLT2-i. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.